Senti Biosciences, Inc. (SNTI)

Senti Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	2.56	4.29	2.76	0.57
Revenue Growth (YoY)	-	-40.25%	55.23%	387.81%	565.88%
Cost of Revenue	34.36	32.15	28.15	21.96	15.96
Gross Profit	-34.36	-29.59	-23.86	-19.2	-15.39
Selling, General & Admin	19.92	34.85	38.23	21.25	9.3
Operating Expenses	19.92	34.85	38.23	21.25	9.3
Operating Income	-54.28	-64.44	-62.08	-40.45	-24.69
Interest & Investment Income	0.95	2.86	1.7	0.01	0.09
Other Non Operating Income (Expenses)	18.07	3.3	-0.03	-0.12	-0.05
EBT Excluding Unusual Items	-35.26	-58.28	-60.42	-40.56	-24.65
Asset Writedown	-0.31	-25.96	-	-0.02	-0.24
Other Unusual Items	-17.22	0.83	10.75	-14.74	5.03
Pretax Income	-52.79	-83.41	-49.67	-55.32	-19.86
Earnings From Continuing Operations	-52.79	-83.41	-49.67	-55.32	-19.86
Earnings From Discontinued Operations	-	12.35	-8.55	-	-
Net Income	-52.79	-71.06	-58.21	-55.32	-19.86
Preferred Dividends & Other Adjustments	2.52	-	-	-	-
Net Income to Common	-55.31	-71.06	-58.21	-55.32	-19.86
Shares Outstanding (Basic)	5	4	3	0	1
Shares Outstanding (Diluted)	5	4	3	0	1
Shares Change (YoY)	3.58%	69.93%	796.58%	-78.99%	2.03%
EPS (Basic)	-12.03	-16.01	-22.29	-189.95	-14.33
EPS (Diluted)	-12.03	-16.01	-22.29	-189.95	-14.33
Free Cash Flow	-41.42	-64.43	-76.27	-40.18	-25.33
Free Cash Flow Per Share	-9.01	-14.52	-29.21	-137.96	-18.27
Operating Margin	-	-2516.28%	-1448.53%	-1464.90%	-4362.90%
Profit Margin	-	-2774.62%	-1358.14%	-2003.59%	-3509.19%
Free Cash Flow Margin	-	-2515.93%	-1779.51%	-1455.20%	-4475.97%
EBITDA	-50.44	-60.88	-60.69	-39.68	-24.13
D&A For EBITDA	3.84	3.56	1.4	0.77	0.56
EBIT	-54.28	-64.44	-62.08	-40.45	-24.69
Revenue as Reported	-	2.56	4.29	2.76	0.57

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q